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Abstract 
 
The leucine rich, glioma inactivated 1 (LGI1)/Epitempin gene has been linked to two phenotypes as 
different as gliomagenesis and autosomal dominant lateral temporal epilepsy. Its function and the 
biochemical features of the encoded protein are unknown. We characterized the LGI1/Epitempin 
protein product by Western blot analysis of mouse and human brain tissues. Two proteins of about 
60 and 65 kDa were detected by an anti-LGI1 antibody within the expected molecular mass range. 
The two proteins appeared to reside in different subcellular compartments, as they were fractionated 
by differential centrifugation. The specificity of  both polypeptides was validated by cell 
transfection assay and mass spectrometry analysis. Immunoblot analysis of protein distribution in 
various zones of the human brain revealed variable amounts of both proteins.  Notably, these 
proteins were more abundant in the temporal neocortex than in the hippocampus, the difference in 
abundance of the 65-kDa product being particularly pronounced. These results suggest that the two 
protein isoforms encoded by LGI1/Epitempin are differentially expressed in the human brain, and 
that higher expression levels of these proteins in the lateral temporal cortex may underlie the 
susceptibility of this brain region to the epileptogenic effects of LGI1/Epitempin mutations.  
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Introduction 
 
The human leucine rich, glioma inactivated 1 (LGI1) gene appears to be involved in malignant 
progression of gliomas  and carries mutations in families with autosomal dominant lateral temporal 
epilepsy (ADLTE), a rare familial partial epilepsy syndrome. This gene was found to be frequently 
downregulated and sometimes rearranged in malignant gliomas (Chernova et al. 1998), suggesting a 
possible tumor suppression function. However, neither  point mutations of the coding region nor 
differential methylation of the LGI1 core promoter region have been demonstrated in these tumors 
(Somerville et al. 2000),  arguing against a role of LGI1 as a tumor suppressor gene. Recent studies 
have suggested that LGI1 may have a role in gliomagenesis as a tumor metastasis suppressor gene 
(Kunapuli et al. 2003; Kunapuli et al. 2004). 
ADLTE, also known as autosomal dominant partial epilepsy with auditory features (ADPEAF), has 
been recognized as a distinct epileptic condition characterized by typical auditory auras and/or 
symptoms suggesting a lateral temporal onset, absence of any brain structural abnormality, and 
benign evolution. Recently, we and others have identified mutations causing ADLTE in LGI1 
(Kalachikov et al. 2002; Morante-Redolat et al. 2002). Numerous additional LGI1 mutations 
resulting in either protein truncation or single amino acid substitutions have been reported 
subsequently (see Ottman et al. 2004), including a de novo mutation (Bisulli et al. 2004). Overall, 
LGI1 mutations have been found in about 50% of ADLTE families (Michelucci et al. 2003; Ottman 
et al. 2004; Berkovic et al. 2004). 
LGI1, which has been renamed Epitempin, is mostly expressed in the brain (Chernova et al. 1998). 
In situ hybridisation experiments have shown that expression of the orthologous murine gene is  
predominantly neuronal (Kalachikov et al. 2002). Both in humans and mice, the main transcription 
product is predicted to encode a protein of  557 amino acids. Computer analysis of the amino acid 
sequence has identified an amino-terminal signal peptide sequence and two distinct structural 
domains, each spanning about half of the protein. The N-terminal half of the protein consists of 3.5 
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leucine-rich repeat (LRR) sequences  flanked on both sides by typical cysteine-rich repeat sequence 
clusters (Kobe and Kajava 2001); the C-terminal half is made of  seven copies of a novel repeat of 
about 45 residues, named epitempin (EPTP; Staub et al. 2002) or epilepsy associated region (EAR; 
Scheel et al. 2002), which is reminiscent of the beta-propeller structural domain (Paoli 2001). The 
same structural disposition of LRR and EPTP/EAR domains has been identified in three putative 
paralogues, named LGI2, LGI3, and LGI4 (Gu et al. 2002; Staub et al. 2002; Scheel et al. 2002). 
LRR and beta-propeller motifs are found in many other proteins and often mediate protein-protein 
interactions.  
Functional studies of  LGI1/Epitempin are still at early stage. Particularly, the biochemical features, 
subcellular localization, and distribution in brain tissues of the protein product have not yet been 
characterized. A few studies have investigated LGI1/Epitempin protein expression  in human and 
mouse brain by immunohistochemistry (Gu et al. 2002; Morante-Redolat et al. 2002), but signal 
specificity of the polyclonal antibodies utilized was poorly characterized.   
In this study, we characterized the basic biochemical features of the LGI1/Epitempin protein 
product and investigated its subcellular localization and distribution in various regions of the human 
brain by Western blot analysis. 
 
Materials and methods 
 
Materials 
 
Reagents for sodium dodecylsulfate-polyacrilamide gel electrophoresis (SDS-PAGE) were 
purchased from Mallinckrodt Baker (Phillipsburg, NJ, USA). Molecular mass standards for SDS-
PAGE (phosphorylase B, albumin, ovalbumin, carbonic anhydrase, trypsin inhibitor, and  α-
lactalbumin, Mr 97, 66, 45, 30, 20,1, and 14,4 kDa, respectively), enhanced chemiluminescence 
(ECL) Western Blotting Detection Reagents, and autoradiography film were from Amersham 
Biosciences (Piscataway, NJ, USA). Phenylmethyl-sulfonyl fluoride (PMSF), benzamidine, 
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leupeptin, bovin serum albumin, EGTA, sucrose,  HEPES, 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) liquid substrate system, nitro blue tetrazolium (NBT), and anti-mouse IgG conjugated to 
alkaline phosphatase secondary antibody were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Nitrocellulose was from Sartorius (Hamburg, Germany). Anti-rabbit  and anti-goat IgG 
conjugated to horseradish peroxydase  secondary antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum 
(FBS) were obtained from Sigma-Aldrich (St. Louis, MO, USA), Opti-MEM and Lipofectamine 
2000 from Invitrogen (Carlsbad, CA,. USA), and trypsin from Promega (Madison, WI, USA). 
 
 
Antibodies 
Six polyclonal antibodies raised against different LGI1/Epitempin peptides were tested: the 
commercially available antibodies sc-9583, sc-9581, and sc-28238 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA); a rabbit antiserum developed by Kunapuli and co-workers (2003) (generous 
gift of Dr. J. K. Cowell); and two additional antisera developed by us (see Morante-Redolat et al. 
2002).  A mouse monoclonal antibody to glyceraldehyde-3phosphate dehydrogenase (GAPDH) was 
from Chemicon (Temecula, CA, USA). 
 
Mouse tissue preparation 
Adult mice (strain C57BL/6J) were used as a source of brain, skeletal muscle, heart, kidney, spleen, 
and liver. Tissues were frozen immediately in liquid nitrogen and stored at –80°C until use. Whole 
homogenates were prepared as described previously (Salvatori et al. 1997). Briefly, tissues were 
homogenized by using an Ultraturrax disperser (20,000 RPM) in the presence of a medium 
containing 3% (wt/vol) sodium dodecylsulfate (SDS), 0,1 mM EGTA, pH 7.0 and a protease 
inhibitor mixture (PMSF and benzamidine 1 mmol/l, leupeptin 0,1 mmol/l). Homogenates were 
then boiled for 5 min and clarified at 15,000xg for 10 min. Supernatants were used as whole protein 
extracts. 
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For mouse brain fractionation all steps were carried out at 4°C. Brains from adult mice were 
homogenized in 0,32 M sucrose, 10 mM HEPES-KOH, pH 7.4 at 4 ml/g of tissue in the presence of 
the above protease inhibitor mixture to minimize protein degradation by using an Ultraturrax 
disperser (13,500 RPM). A post-nuclear supernatant was prepared by centrifugation of the 
homogenate at 3,000xg for 10 mins, and spinned again at 25,000xg for 10 mins. A crude membrane 
fraction was separated from the cytosolic fraction by centrifuging the last supernatant at 35,000xg 
or 105,000xg for 1 hr. The resulting pellet (microsomal fraction) was resuspended in RIPA buffer 
(50mM Tris-HCl pH 8.0, 0.15 M NaCl, 1% (vol/vol) Nonidet P-40, 0.5% (wt/vol) sodium 
deoxycholate, 0.1% (wt/vol) SDS). 
. 
Human brain tissue preparation 
Fresh tissue samples of grey matter from superior frontal gyrus, post-central (parietal) cortex, 
superior temporal gyrus, primary visual (occipital) cortex, and samples from anterior superior 
cerebellar vermis, hippocampus (Ammon’s horn) and putamen were taken from brains of an Italian 
80-year-old male (subject 1) died of heart stroke and a British 70-year-old female (subject 2) died 
of lung carcinoma at the Institute of Anatomic Pathology, Bellaria Hospital, Bologna, Italy and the 
UK Multiple Sclerosis Tissue Bank, respectively. Sampling was performed 12 hours post-mortem. 
Neuropathological examination did not reveal significant pathological abnormalities but ageing 
changes consisting of a few diffuse senile plaques in the frontal and hippocampal cortex. 
Particularly, no metastatic deposits were seen in the brain from subject 2. After removing 
leptomeninges, cortical ribbon was dissected using a magnification lens in order to avoid any 
contamination or white matter. Tissues were frozen in liquid nitrogen straight after sampling and 
then stored at – 70°C. Whole protein homogenates were obtained as described for mouse tissues. 
 
 
Cell culture transfection assay  
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Human embryonic kidney 293 (HEK293) cells were grown in 4 ml DMEM plus 10% (vol/vol) FBS 
on 25 cm2 flasks and transfected with a pcDNA3LGI1 expression construct using Lipofectamine 
2000, following the manufacturer instructions. Twenty-four hours after the beginning of 
transfection cells were washed twice and then re-fed with 4 ml of serum-free medium Opti-MEM. 
Cells were kept in serum-free medium for  about 20 hours. The medium was then collected and 
centrifuged to pellet cell debris, after which  the supernatant was concentrated to about 100 µl using 
Centricon YM30 concentrators (Millipore, Billerica, MA, USA). Twenty-five µl of the concentrated 
medium were loaded on an SDS-PAGE gel and analysed by Western blot. In parallel, we also 
loaded a similarly concentrated medium obtained from cells transfected with pcDNA3 vector alone 
or a green fluorescent protein (GFP) expression construct. Cell extracts were prepared  for 
immunoblotting using Triton lysis buffer ( 25 mM Tris pH 7.4, 150 mM NaCl, 1% (vol/vol) Triton, 
10% (vol/vol) Glycerol, 1mM EDTA) supplemented with proteases inhibitors (Leupeptin 10 µg/ml, 
Aprotinin 10 µg/ml, PMSF 1mM) and phosphatase inhibitors (20mM NaF, 20 mM Na2VO3, β-
glycerophosphate). 
 
Protein analysis 
Protein concentration was determined as described by Bradford (1976), using bovine serum 
albumin as standard. Tissue homogenates, brain tissue fractions, and cell lysates (50 µg/lane), and 
concentrated media were separated on 5-15% SDS-polyacrylamide gels according to Laemmli 
(1970) and then electroblotted onto nitrocellulose membrane. The integrity of the Western blot was 
analysed by Red Ponceau staining. Destained membranes were blocked with 10% (vol/vol) 
skimmed milk in tris-buffered saline (TBS) for 1 hr and then incubated with primary antibody in 
TBS containing 2% (vol/vol) skimmed milk for 2 hrs at room temperature or, in some cases, ON at 
4°C. Proteins immunostained with anti-LGI1 antibody were detected with a horseradish peroxidase-
labelled secondary antibody and enhanced chemiluminescence (ECL) reagent and visualized by 
autoradiography, while GAPDH was detected with an alkaline phosphatase-labeled secondary 
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antibody and visualized by using BCIP/NBT system. Densitometric analysis was performed using 
the Scion Image for Windows software, version Beta 4.0.2 (Scion Corp., Frederick, MD, USA), 
downloaded from the web site: www.scioncorp.com. 
 
Mass spectrometry analysis 
 
Mouse microsomal and cytosolic fraction proteins and HEK293-LGI1 medium proteins were 
resolved by standard SDS-PAGE prior to cutting the relevant lanes of the gel into slices. Those 
slices corresponding to the regions of immunoreactivity with sc-9583 were then subjected to mass 
spectrometry analysis together with control slices. Following de-staining, gel slices were washed 
with 50 mM ammonium bicarbonate and shrinked with ethanol. Reduction/alkylation of proteins 
was performed with 10 mM dithiothreitol (DTT) and 55 mM iodoacetamide. After two wash steps 
with ammonium bicarbonate/ethanol, the gel was dried with ethanol and incubated with 12.5 ng/µl 
trypsin in 50 mM ammonium bicarbonate at 4°C for 15 min. The supernatant was then replaced 
with fresh 50 mM ammonium bicarbonate and the reaction allowed to proceed overnight at 37°C. 
The reaction was stopped with 1% (vol/vol) trifluoroacetic acid (TFA), 0.5% (vol/vol) acetic acid 
and 3% (vol/vol) acetonitrile and the supernatant recovered. Additional peptide extraction steps 
were performed with 30% (vol/vol) acetonitrile and 100% acetonitrile. Supernatants were 
concentrated and then diluted with 0.5% (vol/vol) acetic acid, 30% (vol/vol) acetonitrile, 1% 
(vol/vol) TFA. Peptides were desalted and concentrated on reverse phase C18 StageTips (Rappsilber 
et al 2003). Liquid chromatography was performed on a 20 cm fused silica capillary column (75 µm 
ID) packed in-house with reverse phase C18 material and the eluate was electrosprayed directly into 
a 7 Tesla LTQ-FT mass spectrometer (Thermo Electron, San Jose, CA, USA). Data were acquired 
in data-dependent mode. Fragment ions were searched against the mouse IPI database 
(ftp://ftp.ebi.ac.uk/pub/databases/IPI/current/) using the Mascot server with the following 
parameters: trypsin specificity, two missed cleavages, cysteine carbamidomethylation as a fixed 
modification, methionine oxidation, protein N-terminal acetylation and N/Q deamidation as variable 
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modifications. The mass error of all the identified peptides was below 1 parts per million (ppm) and 
these peptides were matched with the highest score to the LGI1 sequence (“bold red” in Mascot). 
 
Results 
 
Immunoblot analysis of mouse tissues 
In humans and mice, the LGI1/Epitempin protein product is highly conserved (97% identity) and 
has an expected molecular mass of 64 kDa. We tested six polyclonal antibodies raised against 
LGI1/Epitempin peptides (see Materials and Methods) by Western blot analysis of whole cell 
extracts from mouse brain. Five of these antibodies detected weak or no bands around 60 kDa (data 
not shown). The commercially available antibody sc-9583 detected two bands at about 60 and 65 
kDa, the 60-kDa product being far more abundant (Fig. 1 A). None of  these bands was detected in 
other mouse tissues (Fig. 1 A), and detection of both proteins was abolished by blocking the 
primary antibody with the peptide used for immunization (not shown). An additional protein of 
about 22 kDa was recognized only in mouse skeletal muscle (Fig. 1 A), which may represent a 
muscle-specific isoform or a cross-reaction product. 
 
Differential centrifugation of mouse brain homogenates 
To investigate the subcellular localization of the two brain-specific proteins, we performed 
immunoblot analysis of crude microsomal and cytosolic fractions obtained by differential 
centrifugation of whole mouse brain homogenates. The sc-9583 antibody detected the 60-kDa 
protein exclusively in the microsomal fraction, whereas the 65-kDa product was found in the 
cytosolic fraction, where it was considerably enriched (Fig. 1 B). Western blots of microsomal and 
cytosolic fractions were then probed with the other five anti-LGI1 antibodies. The rabbit antiserum 
developed by Kunapuli and colleagues (2003) detected a band of about 65 kDa in the cytosolic 
fraction exactly co-migrating with the cytosolic protein identified by sc-9583, whereas no bands 
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were noted in the microsomal fraction (Fig. 2). Although it cross-reacted with other proteins of 
various molecular masses, this antiserum was previously shown to recognize an LGI1-specific 
polypeptide in extracts from glioblastoma cell lines stably transformed with an LGI1-FLAG 
construct (Kunapuli et al. 2003). Therefore, both Kunapuli’s and sc-9583 antibodies very likely 
recognized the same 65-kDa cytosolic protein that was encoded by LGI1.  
 
Cell culture expression of LGI1/Epitempin 
The proteins expressed by HEK293 cells transiently transfected with an LGI1/Epitempin expression 
construct were analysed by immunoblotting. Both cell lysate and concentrated  (about 40x) serum-
free medium were analysed using the sc-9583 antibody. In the medium, this antibody detected a 
band similar in size to the 60-kDa protein recognized in mouse brain (Fig. 3). No such band was  
detected in the lysate of LGI1-transfected cells or in the medium of HEK293 cells transfected with a 
GFP expression construct as control. The specificity of the protein seen in the medium of LGI1-
transfected cells was confirmed by mass spectrometry analysis: several LGI1-specific peptides were 
identified in a gel-fractionated medium protein sample corresponding to the band immunoreacting 
with the sc-9583 antibody, altogether spanning 28% of the LGI1/Epitempin protein length (see 
Supplementary Table S3). Thus, our results show that the LGI1/Epitempin protein produced in 
transfected HEK293 cells is secreted, confirming the data published recently by Senechal and co-
workers (2005).  
 
Mass spectrometry analysis of mouse brain proteins 
To gain further, more direct, evidence for the specificity of both the 60 and 65 kDa products to 
LGI1/Epitempin, we analysed gel-fractionated mouse brain proteins by mass spectrometry. Protein 
samples resolved by SDS-PAGE and corresponding to the microsomal and cytosolic bands 
recognized by the sc-9583 antibody were cut out of gel, digested with trypsin and analyzed (see 
Materials and Methods). Several LGI1-specific peptides were identified in both samples, spanning  
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25% and 15% of the microsomal and cytosolic protein forms, respectively (Fig. 4; details in 
Supplementary Tables S1 and S2). This finding combined with the results described above strongly 
suggest that the two products recognized by the sc-9583 antibody are protein isoforms encoded by 
LGI1/Epitempin. 
 
Immunoblot analysis of human brain tissues 
To check whether the two proteins detected in the mouse brain by sc-9583 were also expressed in 
the human brain, we performed Western blot analysis of samples of grey matter taken from post-
mortem brains of two individuals with no neurological diseases. Tissue samples from cortical areas 
of the frontal, parietal, occipital, and temporal lobes, and from cerebellum, hippocampus, and 
putamen were analysed. Tissue extracts subjected to immunoblot contained comparable amounts of 
total proteins, as determined by Red Ponceau staining and immunostaining with anti-GAPDH 
antibody (Fig. 5 B).  Both the 60- and 65-kDa proteins were shown by the sc-9583 antibody in most 
human brain samples, and, as in the mouse,  the 60-kDa product was found to be more abundant 
than that of 65 kDa (Fig. 5 A). Expression of the two proteins was considerably different in the 
various tissue samples from the two individuals analysed (Fig. 5 A).  The 65-kDa  protein was 
absent in the cerebellum and was barely detectable in the occipital cortex and hippocampus; higher 
amounts were observed in the parietal and frontal cortices, putamen, and, particularly, in the 
temporal neocortex, where this protein was 3 to 5 times more abundant than in the hippocampus, as 
shown by densitometry (data not shown). Variations in abundance of the 60-kDa product were also 
considerable in some samples (Fig. 5 A), the highest expression level occurring in the occipital 
cortex and the lowest in the hippocampus (2:1 densitometric ratio; data not shown). Although some 
differences in expression pattern were seen, particularly in the cerebellum, comparable band 
intensities were observed in most tissue samples from the two individuals analysed, suggesting that 
the expression variations seen in different brain regions were site-specific.  
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Discussion 
 
The data presented in this paper show that LGI1/Epitempin encodes two proteins of approximately 
60 and 65 kDa, which reside in distinct cell compartments and are differentially expressed in 
various human brain regions.  
The finding of two LGI1/Epitempin protein products may be explained in different ways. Given the 
predicted molecular weight of 64 kDa of the LGI1/Epitempin cDNA translation product, the protein 
of about 65 kDa detected by the sc-9583 antibody may correspond to the full-length protein, 
possibly a precursor or an unprocessed form, and the 60-kDa product  may result from cleavage of 
the putative N-terminal signal peptide. Alternatively, the two protein isoforms may result from 
differential splicing of the LGI1/Epitempin transcript. Because of the small difference between the 
masses of the two polypeptides, the corresponding mRNA  splice isoforms  would presumably 
differ in  size by about 100-150 nucleotides, a difference not detectable by Northern blot. However, 
no ESTs have been identified that are compatible with splice isoforms other than the one predicted 
to encode a short, 292-amino acid, polypeptide spanning the N-terminal LRR domain (Morante-
Redolat et al. 2002).  
Recently, Senechal and collaborators (2005) have shown that the sc-9583 antibody specifically 
recognizes the LGI1/Epitempin protein that is secreted by 293T cells transfected with 
LGI1/Epitempin cDNA. Here, we confirm this result and show that the soluble LGI1/Epitempin 
protein secreted by transfected HEK293 cells seems to correspond to the 60-kDa product detected 
in brain tissues (Fig. 3). Yet, the latter protein was found only in the membrane-enriched fraction 
and not in the soluble fraction obtained from mouse brain tissues. A possible explanation for this is 
that the 60-kDa LGI/Epitempin product, once secreted outside brain cells, binds to other proteins to 
form a protein complex bound to membrane structures. Alternatively,  this protein may undergo 
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processes within neuronal cells very different from those occurring in non-neuronal transfected 
cells, possibly not leading to secretion.  
Cell transfection experiments performed by Senechal and collaborators (2005) also demonstrated 
that the sc-9583 antibody, in addition to recognizing the LGI1/Epitempin product, cross-reacts with 
the LGI3 protein, which is similar in size to LGI1/Epitempin. Yet, in situ hybridisation data by the 
same authors have shown that LGI3 is expressed at low levels throughout the adult mouse brain, the 
highest amount of expression being in the facial nerve nucleus (Senechal et al. 2005). Consistent 
with these mRNA expression data, our mass spectrometry analysis of gel-fractionated mouse brain 
proteins identified several LGI1/Epitempin peptides in both the soluble and membrane protein 
samples immunoreacting with sc-9583, whereas no peptides from LGI3 or other paralogous 
proteins were recognized. This finding together with the results of  LGI1-transfection experiments, 
and the detection of the 65-kDa product by two different anti-LGI1 antibodies (sc-9583 and the 
antiserum by Kunapuli and collaborators (2003)) strongly suggest that both the 60-kDa and 65-kDa 
protein species are encoded by LGI1/Epitempin. 
 
Northern blot analysis has revealed that LGI1/Epitempin is widely expressed in the human brain, 
though with  varying intensity in different brain regions (Chernova et al. 1998). In addition, in situ 
hybridisation experiments have shown that expression of the murine LGI1 gene is higher in some 
areas, particularly in the neocortex and limbic regions (Kalachikov et al. 2002; Senechal et al. 
2005). In keeping with mRNA expression studies, our immunoblotting data clearly showed variable 
expression of both LGI1/Epitempin proteins in the human brain regions investigated, suggesting 
that expression of the LGI1/Epitempin gene may be differentially regulated in different brain 
regions and that such tissue-specific expression may affect neuronal function.  Notably, the 
abundance of the 65-kDa LGI1/Epitempin product was much higher in the lateral temporal cortex 
than in the hippocampus, where this protein species was barely detectable; the 60-kDa product also 
appeared to be more expressed in the temporal neocortex than in the hippocampus,  though the 
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expression difference was less remarkable. Such differential expression of the LGI1/Epitempin 
proteins in the temporal lobe of normal individuals provides a clue to the understanding of the 
molecular mechanisms leading to ADLTE:  expression of higher amounts of these proteins in the 
lateral temporal cortex may underlie the susceptibility of this brain region to the epileptogenic 
effects of LGI1/Epitempin mutations. This possible mechanism should be specific for the lateral 
temporal neurons, since increased amounts of  the LGI1/Epitempin proteins were observed also in 
other cortical regions such as frontal and parietal cortices, from which focal seizures are unlikely to 
originate in epileptic patients with LGI1/Epitempin mutations. Presumably, neurons of these latter 
cortical areas are likely to be involved in circuits different from those involving the temporal cortex 
and/or may produce additional factors exerting protective effects that prevent seizure onset. 
The possibility exists that occurrence of variable amounts of the LGI1/Epitempin proteins in 
different brain regions results from protein transport to specific regions rather than tissue-specific 
expression. Functional studies are needed to clarify this point.  If their functions resemble that of the  
structurally homologous slit protein, a diffusible LRR protein involved in axon guidance and 
neuronal migration (Battye et al. 2001; Wu et al. 1999), then the LGI1/Epitempin products, once 
secreted, are likely to exert their action locally.  
In conclusion, we have identified two protein products very likely encoded by LGI1/Epitempin, 
which are differentially expressed in the temporal cortex, consistent with the lateral temporal 
localization of seizures in patients with LGI1/Epitempin mutations. Further work is needed to 
clarify their  biochemical differences, and to determine their fine distribution across the human  
brain. 
While this paper was under revision, Schulte and co-workers (2006) showed that an LGI1 protein 
product of about 60 kDa is complexed with Kv1.1 potassium channels in neurons of rat 
hippocampus. This protein, the single product recognized by an anti-LGI1 antibody developed by 
these authors, was found in the membrane-enriched fraction obtained from rat brain homogenate 
and was shown to be associated to the neuronal membrane possibly through protein-protein 
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interactions. Because of its molecular mass and subcellular localization, the protein described by 
Schulte and co-workers very likely corresponds to the 60-kDa LGI1 isoform recognized by the sc-
9583 antibody. 
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Fig. 1. A: Immunoblot analysis of mouse tissues with the anti-LGI1 antibody sc-9583. The tissues 
investigated are indicated on top. Molecular weight markers (in kDa) are indicated on the left. B: 
Immunoblot analysis of fractionated mouse brain tissue extract. Cytosolic and microsomal fractions 
obtained by ultracentrifugation of mouse brain homogenate were analyzed with sc-9583. 
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Fig. 2.  Immunoblot analysis of mouse brain protein fractions. Microsomal and cytosolic fractions 
prepared as in Fig. 1 were probed with the sc-9583 antibody (right panel) or the anti-LGI1 
antiserum developed by Kunapuli and co-workers (2003) (left panel). The arrows point to the 
common 65-kDa band. Molecular mass markers are indicated on the left. 
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Fig. 3. Immunoblot analysis of transfected HEK293 cells. Cell lysate and concentrated (about 40x) 
medium of HEK293 cells transfected with an LGI1/Epitempin expression construct (HEK LGI1) or 
with a GFP expression construct (HEK control) were analyzed with the anti-LGI1 antibody sc-9583 
together with a mouse brain homogenate sample. Arrows on the left indicate the LGI1/Epitempin 
60- and 65-kDa proteins detected in whole mouse brain homogenate. 
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 A     
 
     1 MESESSRRMGNACIPLKRIAYFLCLFSVVLLTEGKKPAKPKCPAVCTCSK  
    51 DNALCENARSIPRTVPPDVISLSFVRSGFTEISEGSFLFTPSLQLLLFTS  
   101 NSFDVISDDAFIGLPHLEYLFIENNNIKSISRHTFRGLKSLIHLSLANNN  
   151 LQTLPKDIFKGLDSLTNVDLRGNAFNCDCKLKWLVEWLGHTNATVEDIYC  
   201 EGPPEYKKRKINSLSPKDFDCIITEFAKSQDLPYQSLSIDTFSYLNDEYV  
   251 VIAQPFTGKCIFLEWDHVEKTFRNYDNITGTSTVVCKPIVIDTQLYVIVA  
   301 QLFGGSHIYKRDGFANKFIKIQDIEVLKIRKPNDIETFKIEDNWYFVVAD  
   351 SSKAGFTTIYKWNGNGFYSHQSLHAWYRDTDVEYLEIARPPLALRTPHLI  
   401 LSSSSQRPVIYQWSKATQLFTNQTDIPNMEDVYAVKHFSVKGDVYICLTR  
   451 FIGDSKVMKWGGSSFQDIQRMPSRGSMVFQPLQINNYQYAILGSDYSFTQ  
   501 VYNWDAEKAKFVKFQELNVQAPRSFTHVSINKRNFLFASSFKGNTQIYKH  
   551 VIVDLSA 
 
 
B 
     1 MESESSRRMGNACIPLKRIAYFLCLFSVVLLTEGKKPAKPKCPAVCTCSK  
    51 DNALCENARSIPRTVPPDVISLSFVRSGFTEISEGSFLFTPSLQLLLFTS  
   101 NSFDVISDDAFIGLPHLEYLFIENNNIKSISRHTFRGLKSLIHLSLANNN  
   151 LQTLPKDIFKGLDSLTNVDLRGNAFNCDCKLKWLVEWLGHTNATVEDIYC  
   201 EGPPEYKKRKINSLSPKDFDCIITEFAKSQDLPYQSLSIDTFSYLNDEYV  
   251 VIAQPFTGKCIFLEWDHVEKTFRNYDNITGTSTVVCKPIVIDTQLYVIVA  
   301 QLFGGSHIYKRDGFANKFIKIQDIEVLKIRKPNDIETFKIEDNWYFVVAD  
   351 SSKAGFTTIYKWNGNGFYSHQSLHAWYRDTDVEYLEIARPPLALRTPHLI  
   401 LSSSSQRPVIYQWSKATQLFTNQTDIPNMEDVYAVKHFSVKGDVYICLTR  
   451 FIGDSKVMKWGGSSFQDIQRMPSRGSMVFQPLQINNYQYAILGSDYSFTQ  
   501 VYNWDAEKAKFVKFQELNVQAPRSFTHVSINKRNFLFASSFKGNTQIYKH  
   551 VIVDLSA 
                          
 
Fig. 4. LGI1 peptides identified by mass spectrometry analysis of mouse brain protein 
samples. Grey boxes along the mouse LGI1 amino acid sequence delimit the peptides 
from the microsomal (A) and cytosolic (B) protein forms. 
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Fig. 5. A: Immunoblot analysis of human brain tissue samples from two different individuals. 
Comparable amounts of whole cell protein extracts from samples taken from the brain regions 
indicated were analyzed with the anti-LGI1 antibody sc-9583. Left panel, subject 1; right panel, 
subject 2. The rightmost sample on the right panel is whole mouse brain. Molecular weight markers 
are indicated on the right. B: Immunoblot analysis of the same tissue samples as in A with an 
antibody to GAPDH.    
 
                            
